Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

453
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
453
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world clinical outcomes of lenvatinib+pembrolizumab for the treatment of patients with non-microsatellite instability-high/mismatch repair proficient recurrent or advanced endometrial cancer following prior systemic therapy in the United States.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Findings from the Assessment of real-world Disease characteristics and outcomes in Alopecia Areata in a Global non-Interventional Observational cohort (ADAAGIO) study.

Clinical and experimental dermatology·2025
Same author

Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe.

Breast cancer research and treatment·2025
Same author

Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata.

Dermatology and therapy·2025
Same author

Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia.

Cancer·2025
Same journal

Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios.

Journal of health economics and outcomes research·2026
Same journal

Cost-Effectiveness Analysis of Annual vs Biennial Fecal Immunochemical Testing for Colorectal Cancer Screening in Japan: A Microsimulation Analysis.

Journal of health economics and outcomes research·2026
Same journal

Unlocking the Value of Patient Self-Monitoring Technologies: A Multi-Country Framework to Calibrate Payer and HTA Coverage and Reimbursement Considerations with Innovation.

Journal of health economics and outcomes research·2026
Same journal

Projected Reduction of Diabetes- and Obesity-Related Complication Risks Following the 12-Week Weight-Loss Phase of the RESET Study.

Journal of health economics and outcomes research·2026
Same journal

Real-World Completion of Multitarget Stool DNA Testing Among Texas Medicare Beneficiaries: Associations With Payer Type, Digital Outreach, and Social Vulnerability.

Journal of health economics and outcomes research·2026
Same journal

Cognitive Behavioral Therapy in Early Intervention for Psychosis: A Cost-Effectiveness Analysis.

Journal of health economics and outcomes research·2026
See all related articles

Related Experiment Video

Updated: Jul 17, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel.

Keith L Davis1, Benjamin Gutierrez2, Teresa Zyczynski3

  • 1RTI Health Solutions, Research Triangle Park, NC, USA.

Journal of Health Economics and Outcomes Research
|September 4, 2023
PubMed
Summary
This summary is machine-generated.

Docetaxel with prednisone is a common treatment for castration-resistant prostate cancer (CRPC). However, treatment delays and varied cycle counts suggest potential areas for improved patient care.

Keywords:
castration-resistant prostate cancerdocetaxelmedical record reviewtreatment patterns

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.4K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.8K

Related Experiment Videos

Last Updated: Jul 17, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.4K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.8K

Area of Science:

  • Oncology
  • Urology
  • Clinical Practice Research

Background:

  • Docetaxel is a standard treatment for castration-resistant prostate cancer (CRPC) in the US since 2004.
  • Limited data exists on docetaxel's real-world usage patterns in routine practice.

Purpose of the Study:

  • To investigate the patterns of docetaxel use in patients with CRPC in the United States.
  • To analyze patient demographics, treatment regimens, and reasons for discontinuation.

Main Methods:

  • Retrospective review of medical records for 394 CRPC patients treated between 2004 and 2010.
  • Data collected from oncology and urology practices via an internet-based case report form.
  • Evaluation of patient characteristics, docetaxel regimen details, and concurrent therapies.

Main Results:

  • Most patients initiated docetaxel with prednisone (78.9%).
  • A significant quarter of patients started docetaxel 6 months or later after CRPC diagnosis.
  • Treatment duration varied, with only 10% receiving 10 or more cycles.

Conclusions:

  • Docetaxel and prednisone is the preferred first-line regimen for CRPC, aligning with guidelines.
  • Delayed initiation and variable treatment duration highlight potential areas for optimizing CRPC management.
  • Further research is needed to understand the reasons behind delayed docetaxel initiation and varied exposure durations.